Imexon is primarily investigated for its potential applications in cancer therapy. It functions as a thiol-binding agent, which can induce oxidative stress in cancer cells, leading to their apoptosis. This mechanism makes it a candidate for treating various malignancies, particularly those resistant to conventional therapies. Research has explored its use in combination with other chemotherapeutic agents to enhance efficacy and reduce drug resistance. Additionally, Imexon has been studied for its immunomodulatory effects, which could support the immune system in targeting cancer cells. Its application remains largely experimental, with ongoing clinical trials to determine its safety and effectiveness in treating specific cancer types.